undamentalytics Newsletter
Sign in

Absci Corp key statistics and ratios

In fiscal 2025, Absci Corp had return on equity of -62.5%, an operating margin of -4297.0%, debt equal to 0.5% of equity and a current ratio of 6.57. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Operating margin−278.3%<−999%<−999%<−999%<−999%<−999%<−999%
Net margin−300.3%<−999%<−999%<−999%<−999%<−999%<−999%
Free-cash-flow margin−275.1%<−999%<−999%<−999%<−999%<−999%<−999%
Return on equity—−73.0%−32.8%−49.1%−58.0%−62.5%−55.6%
Return on assets−16.2%−39.2%−28.1%−41.1%−47.9%−53.6%−49.9%
Asset turnover0.050.020.020.020.020.010.01
Current ratio7.258.076.174.084.676.5710.63
Debt to equity—1.6%5.1%6.3%3.8%0.5%0.1%
Interest cover (operating income ÷ interest)n/mn/mn/mn/mn/mn/mn/m
R&D as % of revenue239.5%932.4%>999%840.6%>999%>999%>999%
SG&A as % of revenue115.1%601.8%705.6%661.6%797.8%>999%>999%
Capital spending as % of revenue45.6%795.6%281.5%15.0%8.9%39.5%57.0%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 3 checks passed · June 30, 2026
What it owns · $269m
Short-term assets $208mLonger-term assets $61m
What it owes, and who funded it · $269m
Short-term liabilities $20mLonger-term liabilities $3mShareholders' equity $246m
  • Short-term assets cover short-term liabilities $208m of assets due within a year against $20m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $208m short-term assets against $3m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$126m against $94,000 of interest.

From Absci Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

12 /100

Weak moat

How hard Absci's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -40.0% of total assets over 6 years.

  • Durability 10 / 20

    Operating margin has been a median -2515.2%; its worst year was -8084.5%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 6 years, at a median -1860.1% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (17 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ABSI vs OVIDABSI vs RNACABSI vs DAREABSI vs MCRB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Absci Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Absci Corp.